Relationship between sputum bacterial load and lung function in children with cystic fibrosis receiving tobramycin
Authors:
- Harwood, Kiera
- Duffull, Stephen
- Lai, Tony
- Lei, Alice
- Manning, Sarah
- Pell, Casey
- Ranganathan, Sarath
- Robinson, Phil
- Rogers, Geraint
- Sandaradura, Indy
- Satzke, Catherine
- Shanthikumar, Shivanthan
- Taylor, Steven
- Gwee, Amanda
Details:
Respiratory Medicine, Volume 240, 2025-05-31
Article Link: Click here
Background Chronic pulmonary infection with pathogens such as Pseudomonas aeruginosa is associated with lung function decline and increased mortality in people with cystic fibrosis (CF). The relationship between sputum bacterial load and the severity of pulmonary exacerbations remains unclear. This study aimed to explore the relationship between sputum bacterial load and clinical response to antibiotic treatment of pulmonary exacerbations in children with CF. Methods Multicentre prospective longitudinal study of children with CF receiving IV tobramycin for a pulmonary exacerbation who had prior isolation of Gram-negative bacteria and able to expectorate sputum. Lung function (FEV1) and sputum bacterial load were assessed. Bacterial load was performed using quantitative PCR on either intact (live) bacterial cells or all bacterial DNA (live + dead) and targeted either P. aeruginosa only or all bacteria. Results Twelve children (14 admissions) were enrolled and each provided ≥2 sputum samples; 11 children (13 admissions) also had ≥2 FEV1 measurements. In 10 admissions where FEV1 improved, five showed a reduction in all live bacteria, with a median reduction by 8.65 × 106 copies/g (73 % reduction). Live P. aeruginosa was detected in 8/10 children and in seven, a median reduction of 2.99 × 107 copies/g (90 % reduction) was observed. Improved FEV1 correlated with greater reductions in live + dead P. aeruginosa (ρ = −0.63, p = 0.04). Conclusion A greater reduction in total sputum P. aeruginosa bacterial load (live + dead) was associated with improved lung function (FEV1) in children with CF receiving tobramycin.